Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Griesinger

Showing results (81-90 of 159) with videos related to

Pageof 16
Sort By:
Oncology Research and Treatment|December 3, 2024
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung CancerMaximilian Webendörfer, Sophie Heinzen, Christine Sibbert, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancerSanjay Popat, Odd Terje Brustugun, Jacques Cadranel, et al.
Cancer|March 6, 2002
Radioimmunotherapy of small-volume disease of metastatic colorectal cancerThomas M Behr, Torsten Liersch, Lutz Greiner-Bechert, et al.
JAMA Network Open|November 3, 2022
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology AssessmentSreeram V Ramagopalan, Sanjay Popat, Alind Gupta, et al.
Oncotarget|February 21, 2020
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLCJulia Roeper, Markus Falk, Athena Chalaris-Rißmann, et al.
Cancers|July 2, 2021
Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid BiopsyBalázs Jóri, Stefanie Schatz, Len Kaller, et al.
Cancer|November 7, 2023
Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databasesFrank Griesinger, Sreeram Ramagopalan, Winson Y Cheung, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2021
Neoadjuvant and adjuvant end-points in health technology assessment in oncologyNadia Harbeck, Andreas Schneeweiss, Peter Thuss-Patience, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|July 8, 2025
Long-term survival after treatment in certified lung cancer centers and not certified hospitals: Results of a large German cohort study using clinical routine dataVinzenz Völkel, Michael Gerken, Kees Kleihues-van Tol, et al.
Therapeutic Advances in Medical Oncology|May 17, 2021
Afatinib as first-line treatment in patients with <i>EGFR</i>-mutated non-small cell lung cancer in routine clinical practiceWolfgang M Brückl, Martin Reck, Frank Griesinger, et al.
Pageof 16

Showing results (81-90 of 159) with videos related to

Sort By:
Pageof 16
Oncology Research and Treatment|December 3, 2024
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung CancerMaximilian Webendörfer, Sophie Heinzen, Christine Sibbert, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancerSanjay Popat, Odd Terje Brustugun, Jacques Cadranel, et al.
Cancer|March 6, 2002
Radioimmunotherapy of small-volume disease of metastatic colorectal cancerThomas M Behr, Torsten Liersch, Lutz Greiner-Bechert, et al.
JAMA Network Open|November 3, 2022
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology AssessmentSreeram V Ramagopalan, Sanjay Popat, Alind Gupta, et al.
Oncotarget|February 21, 2020
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLCJulia Roeper, Markus Falk, Athena Chalaris-Rißmann, et al.
Cancers|July 2, 2021
Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid BiopsyBalázs Jóri, Stefanie Schatz, Len Kaller, et al.
Cancer|November 7, 2023
Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databasesFrank Griesinger, Sreeram Ramagopalan, Winson Y Cheung, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2021
Neoadjuvant and adjuvant end-points in health technology assessment in oncologyNadia Harbeck, Andreas Schneeweiss, Peter Thuss-Patience, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|July 8, 2025
Long-term survival after treatment in certified lung cancer centers and not certified hospitals: Results of a large German cohort study using clinical routine dataVinzenz Völkel, Michael Gerken, Kees Kleihues-van Tol, et al.
Therapeutic Advances in Medical Oncology|May 17, 2021
Afatinib as first-line treatment in patients with <i>EGFR</i>-mutated non-small cell lung cancer in routine clinical practiceWolfgang M Brückl, Martin Reck, Frank Griesinger, et al.
Pageof 16